High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza

Journal of Infectious Diseases

Volumn 188, Issue 1, 2003, Pages 57-61

  Shiraishi, Kyoko ^a,b   Mitamura, Keiko ^c   Sakai Tagawa, Yuko ^a   Goto, Hideo ^a   Sugaya, Norio ^c,f   Kawaoka, Yoshihiro ^a,d,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c NIPPON KOKAN HOSPITAL   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f Keiyuu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; PLASMID DNA;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION; GENETIC CODE; HUMAN; INFLUENZA; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION; PREVALENCE; PRIORITY JOURNAL; RNA EXTRACTION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ADOLESCENT; AMANTADINE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFANT; INFLUENZA, HUMAN; MALE; MUTATION; ORTHOMYXOVIRIDAE;

EID: 0037560121     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/375799     Document Type: Article

References (15)

1. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62:1508-12.
2. Wang C, Takeuchi K, Pinto IH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67:5585-94.
3. Crumpacker C. Antiviral therapy. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:393-433.
4. Hayden FG. Amantadine and rimantadine: clinical aspects. In: Richmond DD, ed. Antiviral drug resistance. New York: John Wiley & Sons, 1996:59-77.
5. Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 1989; 159:1050-6.
6. Valette M, Allard JP, Aymard M, Millet V. Susceptibilities to rimantadine of influenza A/H1N1 and A/H3N2 viruses isolated during the epidemics of 1988 to 1989 and 1989 to 1990. Antimicrob Agents Chemother 1993; 37:2239-40.
7. Ziegler T, Hemphill ML, Ziegler ML, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180:935-9.
8. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134:988-97.
9. Houck P, Hemphill M, LaCroix S, et al. Amantadine-resistant influenza A in nursing homes. Arch Intern Med 1995; 155:533-7.
10. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-24.
11. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172:1352-5.
12. Grambas S, Bennett MS, Hay AJ. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 1992; 191:541-9.
13. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. Embo J 1985; 4:3021-4.
14. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994; 68:1551-63.
15. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000;21:700-4.